Novocure saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 67 to 92. The cancer-therapy stock gapped up almost 50% on Tuesday on positive news on its phase 3 trial data of its experimental lung cancer treatment. Is Novocure Stock A Buy?
Read More
